Twist Bioscience (NASDAQ:TWST) Price Target Increased to $45.00 by Analysts at Barclays

Twist Bioscience (NASDAQ:TWST) had its price target upped by Barclays from $40.00 to $45.00 in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

TWST has been the topic of several other reports. The Goldman Sachs Group raised Twist Bioscience from a neutral rating to a buy rating and upped their price target for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th. Scotiabank increased their target price on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a sector outperform rating in a report on Monday, February 5th. Finally, Robert W. Baird lifted their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the company an outperform rating in a report on Friday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Twist Bioscience presently has a consensus rating of Buy and a consensus price target of $41.67.

Twist Bioscience Trading Up 28.7 %

TWST traded up $9.20 during trading on Friday, hitting $41.21. The company had a trading volume of 4,458,430 shares, compared to its average volume of 909,964. Twist Bioscience has a 1-year low of $11.81 and a 1-year high of $43.21. The business has a 50-day moving average of $34.03 and a 200-day moving average of $30.96.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.05. The business had revenue of $75.30 million for the quarter, compared to analysts’ expectations of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 30.81%. The company’s quarterly revenue was up 25.1% compared to the same quarter last year. During the same quarter last year, the company posted ($1.06) earnings per share. As a group, research analysts expect that Twist Bioscience will post -3.17 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Robert Chess sold 4,110 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $34.98, for a total value of $143,767.80. Following the completion of the transaction, the director now directly owns 64,169 shares of the company’s stock, valued at $2,244,631.62. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Twist Bioscience news, Director Robert Chess sold 4,110 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the sale, the director now owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Emily M. Leproust sold 1,128 shares of Twist Bioscience stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total value of $37,810.56. Following the completion of the sale, the chief executive officer now owns 515,281 shares of the company’s stock, valued at $17,272,219.12. The disclosure for this sale can be found here. In the last three months, insiders sold 13,211 shares of company stock valued at $449,573. Company insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC lifted its position in shares of Twist Bioscience by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock worth $265,881,000 after buying an additional 427,274 shares during the last quarter. Artisan Partners Limited Partnership increased its position in shares of Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after acquiring an additional 1,961,621 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Twist Bioscience by 2.9% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock valued at $132,086,000 after purchasing an additional 99,511 shares in the last quarter. Nikko Asset Management Americas Inc. raised its holdings in shares of Twist Bioscience by 2.9% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock worth $131,835,000 after purchasing an additional 99,511 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Twist Bioscience by 29.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock worth $46,732,000 after purchasing an additional 284,884 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.